

RECEIVED
CENTRAL FAX CENTER

Fax

AUG 11 2004



Eli Lilly and Company
Lilly Corporate Center
Indianapolis, Indiana 46285
U.S.A.

Legal Department - Patent Division

To: David Romeo, Ph.D., USPTO



Company: USPTO
Fax: 703-872-9306
Phone: 703-305-4050
Date: August 11, 2004

From: Caren D. Geppert
Fax: 317-276-5172
Phone: 317-651-4215
Total Pages: 9

Re:

Applicant : Edmonds Taylor Brian
Serial No. : 09/763,994
Filed : February 27, 2001
For : Human Latent Transforming Growth
Factor-β Binding Protein 3
Docket No. : X-12239

Privileged and Confidential Communication

If there are any transmittal problems please call: (317) 651-2733.

This facsimile message is intended only for the individual to whom it is addressed and may contain information that is privileged, confidential or exempt from disclosure under applicable law. If you have received this facsimile in error, please notify us immediately by telephone (collect), and return the original message to us at the above address via U.S. Postal Service.

Answers That Matter.

RECEIVED
CENTRAL FAX CENTER

AUG 11 2004

OFFICIAL

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

KELLY L. RAMSEY

Type or print name of person signing certification

Signature

Kelly L. Ramsey

Aug. 11, 2004

Date

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Brian Taylor Edmonds)	Conf. No.:
)	6826
Serial No.	:	09/763,994)	Group Art Unit:
)	1647
Filing Date	:	February 27, 2001)	Examiner:
)	Romeo, David S.
For	:	HUMAN LATENT TRANSFORMING FACTOR- β BINDING PROTEIN 3)	
Docket No.	:	X-12239)	

AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.121

Assistant Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

In response to the Examiner's Office Action bearing an original mailing date of July 30, 2004, Applicants enclose herewith the following amendments and remarks that Applicants believe place the application in condition for allowance. Applicants authorize the office to charge any fees due to Deposit Account No. 05-0840 in the name of Eli Lilly and Company.

Amendments to the Claims are reflected in the listing of claims, which begins on page 2 of this paper.

Remarks begin on page 4 of this paper.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Acting COMMISSIONER FOR PATENTS
 2, T. B. 1450
 Alexandria, Virginia 22213-1450
 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/763,994	02/27/2001	Edmonds Taylor Brink	X-12239	6826

7590 07/30/2004

Robert L Sharp
 Eli Lilly & Company
 Lilly Corporate Center DC1104
 Indianapolis, IN 46285

RECEIVED

AUG 05 2004

ELILLY & COMPANY, PATENT DEPT.

EXAMINER

ROMEO, DAVID S.

ART UNIT

PAPER NUMBER

1647

DATE MAILED: 07/30/2004

Due 8-30-2004

Please find below and/or attached an Office communication concerning this application or proceeding.



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
P.O. Box 1450
ALEXANDRIA, VA 22313-1450
www.uspto.gov

Paper No.

Notice of Non-Compliant Amendment (37 CFR 1.121)

The amendment document filed on 07-19-04 is considered non-compliant because it has failed to meet the requirements of 37 CFR 1.121, as amended on June 30, 2003 (see 68 Fed. Reg. 38611, Jun. 30, 2003). In order for the amendment document to be compliant, correction of the following item(s) is required. Only the corrected section of the non-compliant amendment document must be resubmitted (in its entirety), e.g., the entire "Amendments to the claims" section of applicant's amendment document must be re-submitted. 37 CFR 1.121(b).

THE FOLLOWING CHECKED (X) ITEM(S) CAUSE THE AMENDMENT DOCUMENT TO BE NON-COMPLIANT:

1. Amendments to the specification:
 A. Amended paragraph(s) do not include markings.
 B. New paragraph(s) should not be underlined.
 C. Other _____

2. Abstract:
 A. Not presented on a separate sheet. 37 CFR 1.72.
 B. Other _____

3. Amendments to the drawings: _____

4. Amendments to the claims:
 A. A complete listing of all of the claims is not present.
 B. The listing of claims does not include the text of all claims (including withdrawn claims).
 C. Each claim has not been provided with the proper status identifier, and as such, the individual status of each claim cannot be identified.
 D. The claims of this amendment paper have not been presented in ascending numerical order.
 E. Other: _____

For further explanation of the amendment format required by 37 CFR 1.121, see MPEP Sec. 714 and the USPTO website at <http://www.uspto.gov/web/offices/ac/tp/ops/creativity/officeflyer.pdf>.

If the non-compliant amendment is a PRELIMINARY AMENDMENT, applicant is given ONE MONTH from the mail date of this letter to supply the corrected section which complies with 37 CFR 1.121. Failure to comply with 37 CFR 1.121 will result in non-entry of the preliminary amendment and examination on the merits will commence without consideration of the proposed changes in the preliminary amendment(s). This notice is not an action under 35 U.S.C. 132, and this ONE MONTH time limit is not extendable.

If the non-compliant amendment is a reply to a NON-FINAL OFFICE ACTION (including a submission for an RCE), and since the amendment appears to be a *bona fide* attempt to be a reply (37 CFR 1.135(c)), applicant is given a TIME PERIOD of ONE MONTH from the mailing of this notice within which to re-submit the corrected section which complies with 37 CFR 1.121 in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD ARE AVAILABLE UNDER 37 CFR 1.136(a).

If the amendment is a reply to a FINAL REJECTION, this form may be an attachment to an Advisory Action. The period for response to a final rejection continues to run from the date set in the final rejection, and is not affected by the non-compliant status of the amendment.

Diane Williams
Legal Instruments Examiner (LIE)

571-272-2595
Telephone No.